Johnson & Johnson to Acquire V-Wave for Up to $1.7 Billion

Johnson & Johnson Acquires Atraverse Medical

May 28, 2026

Medical Devices

Johnson & Johnson acquired Atraverse Medical, strengthening its J&J MedTech cardiac electrophysiology portfolio. The acquisition follows the May 15, 2026 close and is referenced in connection with medtech founder John Slump’s subsequent launch of Metis MedTech.

Johnson & Johnson to Acquire Atraverse Medical

April 26, 2026

Medical Devices

Johnson & Johnson entered into a definitive agreement to acquire Atraverse Medical, a privately held medtech company developing the HOTWIRE Transseptal Access System for left-heart access during cardiac electrophysiology procedures. The deal is expected to close in Q2 2026, subject to customary closing conditions, with financial terms not disclosed.

Boston Scientific to Acquire SoniVie Ltd

March 3, 2025

Medical Devices

Boston Scientific Corporation has entered into a definitive agreement to acquire SoniVie Ltd., a privately held medical device company developing the TIVUS intravascular ultrasound system for renal denervation therapy for hypertension. The deal includes an upfront payment of approximately $360 million for the 90% stake Boston Scientific does not already own, plus up to $180 million contingent on achievement of a regulatory milestone.

Johnson & Johnson to Acquire Shockwave Medical for $13.1 Billion

April 5, 2024

Healthcare Services

Johnson & Johnson (JNJ) entered into a definitive agreement to acquire all outstanding shares of Shockwave Medical for $335.00 per share in cash, implying an enterprise value of about $13.1 billion. The deal expands J&J MedTech’s cardiovascular intervention portfolio—adding Shockwave’s intravascular lithotripsy (IVL) technology for calcified coronary and peripheral artery disease.

Shockwave Medical Acquires Neovasc

January 17, 2023

Medical Devices

Shockwave Medical entered into a definitive agreement to acquire Neovasc, a minimally invasive treatment company focused on refractory angina. Under the plan of arrangement, Neovasc shareholders will receive $27.25 per share in upfront cash plus contingent value right (CVR) payments tied to regulatory milestones.

Johnson & Johnson Completes Acquisition of Abiomed

December 22, 2022

Medical Devices

Johnson & Johnson completed its acquisition of Abiomed through a tender offer and subsequent merger, for an upfront payment of $380.00 per share in cash (enterprise value ~ $16.6 billion), plus a non-tradeable contingent value right (CVR) up to $35.00 per share based on milestones. Abiomed will operate as a standalone business within Johnson & Johnson’s MedTech segment.